Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 1/2004

01.01.2004 | Original Article

11C-acetate PET imaging of lung cancer: comparison with 18F-FDG PET and 99mTc-MIBI SPET

verfasst von: Kotaro Higashi, Yoshimichi Ueda, Ichiro Matsunari, Yuko Kodama, Ryosuke Ikeda, Katsuyuki Miura, Suzuka Taki, Takahiro Higuchi, Hisao Tonami, Itaru Yamamoto

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2004

Einloggen, um Zugang zu erhalten

Abstract

Recently carbon-11 acetate (AC) positron emission tomography (PET) has been reported to be of clinical value for the diagnosis of cancer that is negative on fluorine-18 fluorodeoxyglucoce (FDG) PET. We investigated the uptake of AC in lung cancer to determine whether this tracer is of potential value for tumour detection and characterisation, and to compare AC PET imaging with FDG PET and technetium-99m sestamibi (MIBI) single-photon emission tomography (SPET). Twenty-three patients with 25 lung cancers underwent AC and FDG PET. Twenty of 23 patients were also investigated with MIBI SPET. Dynamic images were acquired for 26 min after the injection of 555 MBq of AC. Standardised uptake values (SUVs) and/or tumour to non-tumour activity ratios (T/N) for each tumour were investigated at 10–20 min after AC administration, 40–60 min after administration of 185 MBq FDG and 15–45 min after administration of 555 MBq MIBI. Twenty lung cancers were resected surgically, and the degree of tracer uptake in the primary lesion was correlated with histopathological features (cell dedifferentiation and aggressiveness) and prognosis. Rapid uptake of AC followed by extremely slow clearance was observed. For the purpose of tumour identification, AC PET was inferior to FDG PET in 8 of 25 (32%) lung cancers, and the T/N of AC was lower than that of FDG. However, AC PET was superior to FDG PET in the identification of a slow-growing tumour (bronchiolo-alveolar carcinoma). There was a positive correlation between AC uptake (T/N) and MIBI uptake (T/N) (r=0.799, P<0.0001). A positive correlation was not observed between either AC or MIBI uptake and the degree of cell dedifferentiation in lung adenocarcinomas, whereas FDG uptake did correlate with the degree of cell dedifferentiation. In lung adenocarcinoma, there was a weak correlation between aggressiveness and FDG uptake, but no correlation was evident for AC and MIBI. In addition, a positive correlation was not observed between AC or MIBI uptake and postoperative recurrence in lung adenocarcinoma, whereas FDG uptake did correlate with postoperative recurrence. Thus, the greater the FDG uptake, the higher the malignant grade. In conclusion, for the purpose of tumour identification, AC PET was inferior to FDG PET but superior to MIBI SPET. Neither AC nor MIBI uptake reflects the malignant grade in lung adenocarcinoma, whereas FDG uptake does. AC PET is less diagnostically informative than FDG PET in patients with lung cancer. However, AC PET may play a complementary role in the identification of low-grade malignancies that are not FDG avid.
Literatur
1.
Zurück zum Zitat Strauss LG, Conti PS. The application of PET in clinical oncology. J Nucl Med 1991; 32:623–648.PubMed Strauss LG, Conti PS. The application of PET in clinical oncology. J Nucl Med 1991; 32:623–648.PubMed
2.
Zurück zum Zitat Higashi K, Ueda Y, Sakurai A, et al. Correlation of Glut-1 glucose transporter expression with F-18 FDG uptake in non-small cell carcinoma. Eur J Nucl Med 2000; 27:1778–1785.PubMed Higashi K, Ueda Y, Sakurai A, et al. Correlation of Glut-1 glucose transporter expression with F-18 FDG uptake in non-small cell carcinoma. Eur J Nucl Med 2000; 27:1778–1785.PubMed
3.
Zurück zum Zitat Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998; 39:1016–1020.PubMed Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998; 39:1016–1020.PubMed
4.
Zurück zum Zitat Higashi K, Ueda Y, Yagishita M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 2000; 41:85–92.PubMed Higashi K, Ueda Y, Yagishita M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 2000; 41:85–92.PubMed
5.
Zurück zum Zitat Higashi K, Ueda Y, Ayabe K, et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun 2000; 21:707–714.PubMed Higashi K, Ueda Y, Ayabe K, et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun 2000; 21:707–714.PubMed
6.
Zurück zum Zitat Higashi K, Ueda Y, Arisaka Y, et al. F-18 FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002; 43:39–45. Higashi K, Ueda Y, Arisaka Y, et al. F-18 FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002; 43:39–45.
7.
Zurück zum Zitat Erasmus JJ, McAdams HP, Patz EF, et al. Evaluation of primary pulmonary carcinoid tumours using FDG PET. Am J Roentgenol 1998; 170:1369–1373. Erasmus JJ, McAdams HP, Patz EF, et al. Evaluation of primary pulmonary carcinoid tumours using FDG PET. Am J Roentgenol 1998; 170:1369–1373.
8.
Zurück zum Zitat Kao CH, Wang SJ, Lin WY, et al. Differentiation of single solid lesions in the lungs by means of single-photon emission tomography with technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med 1993; 20:249–254.PubMed Kao CH, Wang SJ, Lin WY, et al. Differentiation of single solid lesions in the lungs by means of single-photon emission tomography with technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med 1993; 20:249–254.PubMed
9.
Zurück zum Zitat Komori T, Narabayashi I, Matsui R, et al. Evaluation of uptake and release of technetium-99m MIBI SPET of pulmonary and mediastinal lesions. Ann Nucl Med 1997; 11:227–232.PubMed Komori T, Narabayashi I, Matsui R, et al. Evaluation of uptake and release of technetium-99m MIBI SPET of pulmonary and mediastinal lesions. Ann Nucl Med 1997; 11:227–232.PubMed
10.
Zurück zum Zitat Wang H, Maura S, Mainolfi C, et al. Tc-99m MIBI scintigraphy in patients with lung cancer comparison with CT and fluorine-18 FDG PET imaging. Clin Nucl Med 1997; 22:243–249.CrossRefPubMed Wang H, Maura S, Mainolfi C, et al. Tc-99m MIBI scintigraphy in patients with lung cancer comparison with CT and fluorine-18 FDG PET imaging. Clin Nucl Med 1997; 22:243–249.CrossRefPubMed
11.
Zurück zum Zitat Chiu MI, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutysonitrile) technetium (I) in cultured mouse fibroblasts. J Nucl Med 1990; 31:1646–1653.PubMed Chiu MI, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutysonitrile) technetium (I) in cultured mouse fibroblasts. J Nucl Med 1990; 31:1646–1653.PubMed
12.
Zurück zum Zitat Crane P, Laliberte R, Heminway S, et al. Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention. Eur J Nucl Med 1993; 20:20–25.PubMed Crane P, Laliberte R, Heminway S, et al. Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention. Eur J Nucl Med 1993; 20:20–25.PubMed
13.
Zurück zum Zitat Abdel-Dayem HM, Scott A, Macapinlac H, et al. Tracer imaging in lung cancer. Eur J Nucl Med 1994; 21:57–81.PubMed Abdel-Dayem HM, Scott A, Macapinlac H, et al. Tracer imaging in lung cancer. Eur J Nucl Med 1994; 21:57–81.PubMed
14.
15.
Zurück zum Zitat Shreve P, Chiao PC, Humes HD, et al. Carbon-11-acetate PET imaging in renal disease. J Nucl Med 1995; 36:1595–1601.PubMed Shreve P, Chiao PC, Humes HD, et al. Carbon-11-acetate PET imaging in renal disease. J Nucl Med 1995; 36:1595–1601.PubMed
16.
Zurück zum Zitat Shreve PD, Gross MD. Imaging of the pancreas and related diseases with PET carbon-11-acetate. J Nucl Med 1997; 38:1305–1310.PubMed Shreve PD, Gross MD. Imaging of the pancreas and related diseases with PET carbon-11-acetate. J Nucl Med 1997; 38:1305–1310.PubMed
17.
Zurück zum Zitat Oyama N, Akino H, Kanamaru H, et al. C-11 acetate PET imaging of prostate cancer. J Nucl Med 2002; 43:181–186.PubMed Oyama N, Akino H, Kanamaru H, et al. C-11 acetate PET imaging of prostate cancer. J Nucl Med 2002; 43:181–186.PubMed
18.
Zurück zum Zitat Shreve PD. Carbon-11 acetate PET imaging of prostatic cancer [abstract]. J Nucl Med 1999; 40 (Suppl):60P. Shreve PD. Carbon-11 acetate PET imaging of prostatic cancer [abstract]. J Nucl Med 1999; 40 (Suppl):60P.
19.
Zurück zum Zitat Yeh SH, Liu RS, Wu LC, et al.11C-acetate clearance in nasopharyngeal carcinoma. Nucl Med Commun 1999; 20:131–134.PubMed Yeh SH, Liu RS, Wu LC, et al.11C-acetate clearance in nasopharyngeal carcinoma. Nucl Med Commun 1999; 20:131–134.PubMed
20.
Zurück zum Zitat Liu RS, Chu YK, Chu LS, et al. C-11 acetate PET imaging in detection and characterization of lung cancer [abstract]. J Nucl Med 2001; 43(Suppl):7P. Liu RS, Chu YK, Chu LS, et al. C-11 acetate PET imaging in detection and characterization of lung cancer [abstract]. J Nucl Med 2001; 43(Suppl):7P.
21.
Zurück zum Zitat Liu RS, Shei HR, Feng CF, et al. Combined F-18 FDG and C-11 Acetate PET imaging in pulmonary carcinoma [abstract]. J Nucl Med 2002; 43(Suppl):127P. Liu RS, Shei HR, Feng CF, et al. Combined F-18 FDG and C-11 Acetate PET imaging in pulmonary carcinoma [abstract]. J Nucl Med 2002; 43(Suppl):127P.
22.
Zurück zum Zitat Ho C, Yeung DW. C-11 acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003; 44:213–221.PubMed Ho C, Yeung DW. C-11 acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003; 44:213–221.PubMed
23.
Zurück zum Zitat Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumour cells in relation to cell proliferation: acetate metabolism in tumour cells. Nucl Med Biol 2001; 28:117–122.PubMed Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumour cells in relation to cell proliferation: acetate metabolism in tumour cells. Nucl Med Biol 2001; 28:117–122.PubMed
24.
Zurück zum Zitat Oyama N, Kim J, Jones LA, et al. MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and prostate cancer tumour model. Nucl Med Biol 2002; 29:783–790.CrossRefPubMed Oyama N, Kim J, Jones LA, et al. MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and prostate cancer tumour model. Nucl Med Biol 2002; 29:783–790.CrossRefPubMed
25.
Zurück zum Zitat Hassan IM, Sahweil A, Constantinides C, et al. Uptake and kinetics of Tc-99m hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs. Clin Nucl Med 1989; 14:333–340.PubMed Hassan IM, Sahweil A, Constantinides C, et al. Uptake and kinetics of Tc-99m hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs. Clin Nucl Med 1989; 14:333–340.PubMed
Metadaten
Titel
11C-acetate PET imaging of lung cancer: comparison with 18F-FDG PET and 99mTc-MIBI SPET
verfasst von
Kotaro Higashi
Yoshimichi Ueda
Ichiro Matsunari
Yuko Kodama
Ryosuke Ikeda
Katsuyuki Miura
Suzuka Taki
Takahiro Higuchi
Hisao Tonami
Itaru Yamamoto
Publikationsdatum
01.01.2004
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2004
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-003-1326-7

Weitere Artikel der Ausgabe 1/2004

European Journal of Nuclear Medicine and Molecular Imaging 1/2004 Zur Ausgabe